JP2020527156A5 - - Google Patents

Download PDF

Info

Publication number
JP2020527156A5
JP2020527156A5 JP2020502477A JP2020502477A JP2020527156A5 JP 2020527156 A5 JP2020527156 A5 JP 2020527156A5 JP 2020502477 A JP2020502477 A JP 2020502477A JP 2020502477 A JP2020502477 A JP 2020502477A JP 2020527156 A5 JP2020527156 A5 JP 2020527156A5
Authority
JP
Japan
Prior art keywords
cladribine
composition according
amount
effective
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020502477A
Other languages
English (en)
Japanese (ja)
Other versions
JP7186214B2 (ja
JP2020527156A (ja
Filing date
Publication date
Priority claimed from GB1711800.1A external-priority patent/GB2564717A/en
Application filed filed Critical
Publication of JP2020527156A publication Critical patent/JP2020527156A/ja
Publication of JP2020527156A5 publication Critical patent/JP2020527156A5/ja
Application granted granted Critical
Publication of JP7186214B2 publication Critical patent/JP7186214B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020502477A 2017-07-21 2018-06-28 自己免疫性神経筋疾患を処置するためのクラドリビンの使用 Active JP7186214B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1711800.1 2017-07-21
GB1711800.1A GB2564717A (en) 2017-07-21 2017-07-21 Use of cladribine for treating autoimmune neuromuscular disease
PCT/GB2018/051801 WO2019016505A1 (en) 2017-07-21 2018-06-28 USE OF CLADRIBINE FOR THE TREATMENT OF AUTOIMMUNE NEUROMUSCULAR DISEASE

Publications (3)

Publication Number Publication Date
JP2020527156A JP2020527156A (ja) 2020-09-03
JP2020527156A5 true JP2020527156A5 (enExample) 2021-05-27
JP7186214B2 JP7186214B2 (ja) 2022-12-08

Family

ID=59771723

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020502477A Active JP7186214B2 (ja) 2017-07-21 2018-06-28 自己免疫性神経筋疾患を処置するためのクラドリビンの使用

Country Status (16)

Country Link
US (2) US12171775B2 (enExample)
EP (2) EP4292663A3 (enExample)
JP (1) JP7186214B2 (enExample)
CA (1) CA3095893A1 (enExample)
DK (1) DK3654989T3 (enExample)
ES (1) ES2974423T3 (enExample)
FI (1) FI3654989T3 (enExample)
GB (1) GB2564717A (enExample)
HR (1) HRP20240282T1 (enExample)
HU (1) HUE066238T2 (enExample)
LT (1) LT3654989T (enExample)
PL (1) PL3654989T3 (enExample)
PT (1) PT3654989T (enExample)
RS (1) RS65246B1 (enExample)
SI (1) SI3654989T1 (enExample)
WO (1) WO2019016505A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease
TW202541818A (zh) 2023-12-14 2025-11-01 瑞士商亞利斯貿易公司 用於治療重症肌無力之克拉屈濱(cladribine)療程

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
EP1200102A1 (en) * 1999-07-22 2002-05-02 Supergen, Inc. Methods for treating autoimmune diseases
EP1556010A4 (en) * 2002-10-31 2007-12-05 Supergen Inc PHARMACEUTICAL FORMULATIONS; WHICH ARE ADDRESSED TO CERTAIN REGIONS OF THE STOMACH-DARM TRAKTS
WO2004049195A2 (en) * 2002-11-22 2004-06-10 Transclick, Inc. System and method for language translation via remote devices
KR20060011943A (ko) 2003-03-28 2006-02-06 아이박스 코포레이션 향상된 경구 및 경점막 수송용 클라드리빈 제형
DK2805723T3 (da) 2004-12-22 2018-01-29 Merck Serono Sa Cladribin-regime til behandling af multipel sclerose
MX2008014971A (es) * 2006-05-24 2008-12-05 Serono Lab Regimen de cladribine para tratar esclerosis multiple.

Similar Documents

Publication Publication Date Title
KR101900520B1 (ko) 복합 조성물
RU2014109074A (ru) ИНГИБИТОРЫ ФАННИ-ТОКА (If), ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ В СПОСОБЕ ЛЕЧЕНИЯ И ПРЕДУПРЕЖДЕНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У КОШАЧЬИХ
JP2016521755A5 (enExample)
HRP20140592T1 (hr) Poboljšani medicinski pripravci koji sadrže buprenorfin i naltrekson
RU2012133528A (ru) Способ лечения аутоиммунного демиелинизирующего заболевания центральной нервной системы (варианты)
JP2010524882A5 (enExample)
JP2016505050A5 (enExample)
JP2020527156A5 (enExample)
JP2012505830A5 (enExample)
HRP20240812T1 (hr) Oblici doziranja i terapijska primjena l-4-klorokinurenina
RU2011111792A (ru) Применение парацетамола и ибупрофена в лечении
MY195178A (en) Composition for Treating Joint Disease and Kit Containing Same
CN101480392A (zh) 草乌甲素作为制备治疗与Na+通道相关疼痛药物的应用
FI3654989T3 (fi) Kladribiinin käyttö neuromuskulaarisen autoimmuunisairauden hoitoon
CN111434335A (zh) 绿原酸在制备预防或治疗疼痛的药物或药物组合物中的用途
FI3919060T3 (fi) Ecopipam touretten oireyhtymän hoitoon
EP3554489A1 (en) Treatment of moderate and severe gastroparesis
JP2014530249A5 (enExample)
CN104434948B (zh) 一种抗胰腺癌的药物组合物及其应用
JPH01221316A (ja) 脳循環代謝改善剤
ES2376023T3 (es) Utilización de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos craneales.
CN106806382B (zh) 抗癌组合物
CN103239444A (zh) 右旋吲哚布芬与氯吡格雷的复方药物组合物
CN1332664C (zh) 鼻粉剂
TW200526197A (en) Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors